Stock AnalizCelcuity Inc. CELC
Medical Specialities · IPO 2017 · data as of November 13, 2026
Celcuity Inc. (CELC) is a healthcare company listed in the US with a market value of about $3.2B.
Its overall Stock Analiz score is 0.0 out of 5 (weak). The strongest part is value (0/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -34%.
Score: 0.0 / 5
Checks passed
- —
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — | — | — |
| Net income | -$177M | -$112M | -$64M | -$40M | -$30M | -$9M | -$7M | -$7M | -$6M | -$3M |
| Free cash flow | -$154M | -$84M | -$54M | -$36M | -$20M | -$7M | -$6M | -$7M | -$5M | -$3M |
| EPS (diluted) | $-3.79 | $-2.83 | $-2.69 | $-2.64 | $-2.21 | $-0.92 | $-0.72 | $-0.74 | $-0.84 | $-0.52 |
| Net margin | — | — | — | — | — | — | — | — | — | — |
| ROIC | -57.1% | -40.5% | -29.4% | -18.3% | -26.4% | -80.0% | -40.0% | -31.3% | -19.0% | -59.3% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 13 analysts is $150.85, 134% above the current price; targets range from $130.00 to $177.00; the consensus rating is “Strong buy”; expected EPS is $-4.28 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Celcuity pay a dividend?
Not currently.
Is Celcuity a good stock to buy?
We do not give buy or sell advice. Celcuity scores 0.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.